BrainsWay Ltd. (BRSYF)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
BrainsWay Ltd. (BRSYF) with AI Score 62/100 (Hold). BrainsWay Ltd. specializes in noninvasive neurostimulation treatments for mental health disorders, utilizing its Deep Transcranial Magnetic Stimulation (dTMS) platform. Market cap: 0, Sector: Healthcare.
Last analyzed: Mar 17, 2026BrainsWay Ltd. (BRSYF) Healthcare & Pipeline Overview
BrainsWay Ltd. is a medical device company focused on developing and commercializing its Deep Transcranial Magnetic Stimulation (dTMS) platform for treating various mental health disorders. With a presence in the US, Europe, and Israel, BrainsWay caters to the psychiatry sector, offering non-invasive neurostimulation solutions.
Investment Thesis
BrainsWay Ltd. presents a focused investment opportunity within the neurostimulation segment of the medical device industry. The company's dTMS technology addresses a significant market need for non-invasive mental health treatments. With a P/E ratio of 64.24 and a profit margin of 14.6%, BrainsWay demonstrates profitability, although the P/E suggests a high valuation. The company's gross margin of 75.4% indicates strong pricing power and efficient operations. Growth catalysts include expanding applications of dTMS technology and increasing adoption in key markets. However, potential risks include competition from other neurostimulation technologies and the need for continued clinical validation of dTMS efficacy across various indications.
Based on FMP financials and quantitative analysis
Key Highlights
- Market capitalization of $0.47 billion indicates a mid-sized company in the medical device sector.
- P/E ratio of 64.24 suggests investors have high expectations for future earnings growth.
- Profit margin of 14.6% demonstrates the company's ability to generate profits from its revenue.
- Gross margin of 75.4% highlights efficient cost management and strong pricing power.
- Beta of 1.46 suggests the stock is more volatile than the overall market.
Competitors & Peers
Strengths
- Proprietary Deep TMS technology.
- Clinical evidence supporting efficacy.
- Established presence in key markets.
- High gross margin.
Weaknesses
- Limited product portfolio.
- Reliance on dTMS technology.
- Relatively small market capitalization.
- High P/E ratio.
Catalysts
- Ongoing: Expansion of dTMS applications to new therapeutic areas.
- Ongoing: Geographic expansion into underserved markets.
- Upcoming: Potential strategic partnerships and acquisitions.
- Ongoing: Increased adoption of dTMS in psychiatry.
- Ongoing: Development of next-generation dTMS technology.
Risks
- Potential: Competition from alternative neurostimulation technologies.
- Potential: Regulatory changes affecting medical device approvals.
- Potential: Reimbursement challenges from healthcare providers.
- Potential: Economic downturns impacting healthcare spending.
- Ongoing: Dependence on the success of dTMS technology.
Growth Opportunities
- Expanding dTMS Applications: BrainsWay has the opportunity to expand the applications of its dTMS technology beyond its current indications, such as MDD and OCD. Exploring new therapeutic areas like Alzheimer's disease, autism, and chronic pain could significantly increase the addressable market. Clinical trials and research collaborations will be crucial for validating the efficacy of dTMS in these new areas. Success in these areas could open up new revenue streams and establish BrainsWay as a leader in non-invasive treatment options for a wider range of neurological and psychiatric disorders.
- Geographic Expansion: BrainsWay can pursue growth by expanding its geographic presence, particularly in underserved markets. Entering new regions in Asia, South America, and Africa could provide access to a large patient population. This expansion would require establishing partnerships with local distributors and healthcare providers, as well as obtaining regulatory approvals in each new market. Successful geographic expansion could diversify BrainsWay's revenue streams and reduce its reliance on existing markets.
- Strategic Partnerships and Acquisitions: BrainsWay can explore strategic partnerships and acquisitions to enhance its technology and market reach. Collaborating with other medical device companies or research institutions could accelerate the development of new dTMS applications. Acquiring complementary technologies or companies could expand BrainsWay's product portfolio and market share. These partnerships and acquisitions could provide access to new expertise, resources, and distribution channels.
- Increased Adoption in Psychiatry: BrainsWay can focus on increasing the adoption of its dTMS system among psychiatrists and mental health professionals. This can be achieved through targeted marketing campaigns, educational programs, and clinical training. Demonstrating the clinical and economic benefits of dTMS compared to traditional treatments, such as medication and electroconvulsive therapy (ECT), will be essential for driving adoption. Increased adoption in psychiatry could lead to a significant increase in BrainsWay's revenue and market share.
- Development of Next-Generation dTMS Technology: BrainsWay can invest in the development of next-generation dTMS technology to improve its efficacy, safety, and ease of use. This could involve developing new coil designs, stimulation protocols, and software algorithms. Incorporating advanced technologies, such as artificial intelligence and machine learning, could further enhance the performance of the dTMS system. The development of next-generation technology could maintain BrainsWay's competitive advantage and attract new customers.
Opportunities
- Expanding dTMS applications.
- Geographic expansion.
- Strategic partnerships and acquisitions.
- Increased adoption in psychiatry.
Threats
- Competition from alternative neurostimulation technologies.
- Regulatory changes.
- Reimbursement challenges.
- Economic downturns.
Competitive Advantages
- Proprietary Deep Transcranial Magnetic Stimulation (dTMS) technology.
- Established clinical evidence supporting the efficacy of dTMS.
- Strong relationships with key opinion leaders in psychiatry.
- Regulatory approvals for dTMS in major markets.
About BRSYF
Founded in 2003 and headquartered in Jerusalem, Israel, BrainsWay Ltd. is a medical device company specializing in the development and commercialization of noninvasive neurostimulation treatments for mental health disorders. The company's core technology is the Deep Transcranial Magnetic Stimulation (dTMS) platform, which is designed to treat a range of conditions, including major depressive disorder (MDD), anxious depression, obsessive-compulsive disorder (OCD), and smoking addiction. BrainsWay's dTMS system is also being explored for potential applications in bipolar disorder, post-traumatic stress disorder (PTSD), schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post-stroke rehabilitation, and Parkinson's disease. BrainsWay primarily serves doctors, hospitals, and medical centers in the field of psychiatry. The company has expanded its reach to the United States, Europe, and Israel, establishing a global presence in the mental health treatment market. BrainsWay's focus on non-invasive solutions positions it within a growing segment of the medical device industry, driven by increasing demand for effective and accessible mental health treatments.
What They Do
- Develops Deep Transcranial Magnetic Stimulation (dTMS) technology.
- Offers noninvasive neurostimulation treatments for mental health disorders.
- Provides dTMS systems for the treatment of major depressive disorders.
- Addresses anxious depression and obsessive-compulsive disorders.
- Offers solutions for smoking addiction.
- Explores applications in bipolar disorders, PTSD, and schizophrenia.
- Investigates dTMS for Alzheimer's disease, autism, and chronic pain.
- Serves doctors, hospitals, and medical centers in psychiatry.
Business Model
- Sells Deep Transcranial Magnetic Stimulation (dTMS) systems to medical facilities.
- Generates revenue through the sale of disposable treatment coils.
- Provides training and support services for dTMS system users.
- Pursues research and development collaborations to expand dTMS applications.
Industry Context
BrainsWay operates in the medical device industry, specifically within the neurostimulation market. This market is driven by increasing prevalence of mental health disorders and growing demand for non-invasive treatment options. The competitive landscape includes companies offering alternative neurostimulation technologies and pharmaceutical treatments. BrainsWay's dTMS platform differentiates itself through its deep stimulation capabilities and expanding clinical applications. The global market for neurostimulation devices is projected to grow, driven by technological advancements and increasing awareness of mental health issues.
Key Customers
- Psychiatrists and mental health professionals.
- Hospitals and medical centers.
- Research institutions.
- Patients seeking noninvasive mental health treatments.
Financials
Chart & Info
BrainsWay Ltd. (BRSYF) stock price: Price data unavailable
Latest News
-
Undiscovered Middle East Gems To Explore In February 2026
Simply Wall St. · Feb 11, 2026
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for BRSYF.
Price Targets
Wall Street price target analysis for BRSYF.
MoonshotScore
What does this score mean?
The MoonshotScore rates BRSYF's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Hadar Levy
CEO
Hadar Levy serves as the CEO of BrainsWay Ltd. His background includes extensive experience in the medical device industry, with a focus on commercialization and market development. He has a proven track record of driving revenue growth and expanding market share for innovative medical technologies. Before joining BrainsWay, Hadar held leadership positions at several prominent medical device companies, where he was responsible for developing and executing successful commercial strategies.
Track Record: Since becoming CEO, Hadar Levy has focused on expanding the clinical applications of BrainsWay's dTMS technology and increasing its adoption among psychiatrists. He has overseen the launch of new dTMS products and the expansion of BrainsWay's geographic presence. Under his leadership, BrainsWay has achieved significant revenue growth and strengthened its position in the neurostimulation market.
BRSYF OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that BrainsWay Ltd. (BRSYF) may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier may have limited financial disclosure, making it more difficult for investors to assess their financial health and operational performance. Investing in companies on the OTC Other tier carries a higher degree of risk compared to those listed on major exchanges like the NYSE or NASDAQ due to the potential for less stringent regulatory oversight and lower liquidity.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure.
- Lower liquidity compared to major exchanges.
- Potential for increased price volatility.
- Less stringent regulatory oversight.
- Higher risk of fraud or manipulation.
- Verify the company's financial statements.
- Research the company's management team and their track record.
- Assess the company's business model and competitive landscape.
- Review the company's regulatory filings and compliance history.
- Understand the risks associated with investing in OTC stocks.
- Consult with a financial advisor.
- Check for any legal or regulatory actions against the company.
- Established history of operations since 2003.
- Proprietary Deep Transcranial Magnetic Stimulation (dTMS) technology.
- Clinical evidence supporting the efficacy of dTMS.
- Presence in the United States, Europe, and Israel.
- Serves doctors, hospitals, and medical centers in psychiatry.
BRSYF Healthcare Stock FAQ
What does BrainsWay Ltd. do?
BrainsWay Ltd. develops and commercializes Deep Transcranial Magnetic Stimulation (dTMS) systems for the treatment of mental health disorders. Their primary product is a non-invasive neurostimulation device used to treat conditions like major depressive disorder, obsessive-compulsive disorder, and smoking addiction. The company's business model revolves around selling these dTMS systems to hospitals, clinics, and psychiatric practices, along with providing ongoing support and training. BrainsWay operates in the growing market for non-pharmacological treatments for mental health, offering an alternative to traditional medication-based approaches.
What do analysts say about BRSYF stock?
As of 2026-03-17, a comprehensive analyst consensus for BRSYF is pending AI analysis. Key valuation metrics to consider include the company's P/E ratio of 64.24, which suggests a premium valuation. Growth considerations revolve around the expansion of dTMS applications and geographic reach. Investors should monitor analyst reports for updates on revenue projections, earnings estimates, and target prices. However, it's essential to conduct independent research and consider individual investment objectives before making any decisions.
What are the main risks for BRSYF?
The main risks for BrainsWay Ltd. include competition from other neurostimulation technologies, such as transcranial direct current stimulation (tDCS) and vagus nerve stimulation (VNS). Regulatory changes and reimbursement challenges could also impact the company's ability to commercialize its dTMS system. Additionally, the success of BrainsWay is highly dependent on the continued clinical validation and adoption of its dTMS technology. Economic downturns could affect healthcare spending and reduce demand for non-essential medical treatments.
What are the key factors to evaluate for BRSYF?
BrainsWay Ltd. (BRSYF) currently holds an AI score of 62/100, indicating moderate score. Key strength: Proprietary Deep TMS technology.. Primary risk to monitor: Potential: Competition from alternative neurostimulation technologies.. This is not financial advice.
How frequently does BRSYF data refresh on this page?
BRSYF prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven BRSYF's recent stock price performance?
Recent price movement in BrainsWay Ltd. (BRSYF) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Proprietary Deep TMS technology.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider BRSYF overvalued or undervalued right now?
Determining whether BrainsWay Ltd. (BRSYF) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying BRSYF?
Before investing in BrainsWay Ltd. (BRSYF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- AI analysis pending for BRSYF, limiting comprehensive insights.
- OTC market carries inherent risks due to lower regulation and liquidity.